1. Home
  2. YMM vs CYTK Comparison

YMM vs CYTK Comparison

Compare YMM & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YMM

Full Truck Alliance Co. Ltd. (each representing 20)

HOLD

Current Price

$8.76

Market Cap

9.1B

Sector

Technology

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$72.39

Market Cap

10.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YMM
CYTK
Founded
2011
1997
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1B
10.7B
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
YMM
CYTK
Price
$8.76
$72.39
Analyst Decision
Hold
Strong Buy
Analyst Count
3
19
Target Price
$12.00
$89.26
AVG Volume (30 Days)
7.0M
1.8M
Earning Date
05-21-2026
05-05-2026
Dividend Yield
4.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
N/A
$7.37
Revenue Next Year
$13.05
$310.19
P/E Ratio
$18.30
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.46
$44.93
52 Week High
$14.07
$88.31

Technical Indicators

Market Signals
Indicator
YMM
CYTK
Relative Strength Index (RSI) 45.95 40.68
Support Level $8.27 $73.34
Resistance Level $9.52 $79.66
Average True Range (ATR) 0.25 2.14
MACD -0.05 0.07
Stochastic Oscillator 43.23 27.81

Price Performance

Historical Comparison
YMM
CYTK

About YMM Full Truck Alliance Co. Ltd. (each representing 20)

Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: